NICE draft guidance says 'No' to Roche's Gazyvaro

14 September 2016
2019_biotech_test_vial_discovery_big

The UK’s National Institute for Health and Care Excellence (NICE) has today published draft guidance that does not recommend Swiss pharma giant Roche’s (ROG: SIX) Gazyvaro/Gazyva (obinutuzumab) with bendamustine for treating some people with follicular lymphoma – a type of non-Hodgkin’s lymphoma.

Obinutuzumab with bendamustine is used to treat follicular lymphoma in people who did not respond to, or whose condition has progressed after treatment with, rituximab – containing regimens (current standard treatment that targets lymphoma cells).

The NICE appraisal committee concluded that there were uncertainties in the evidence for obinutuzumab with bendamustine which meant that the overall survival gain of patients was unclear, so could not recommend the drug as a cost-effective use of NHS resources. The committee noted that an updated analysis from the pivotal trial for the drug will soon be available.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology